Concordance and Accuracy of MRI in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium

NCT04113395 | Completed

• 1 other identifier: ALR_2019_14
• Study Type: observational
• Target: 514
• Locations: 1 country
• Sites: 10

Brief Summary

Meningioma, an extra-axial brain tumor developed at the expense of meninges, accounts for 35% of central nervous system tumors, and its incidence is estimated at 3% in large autopsy series. The current gold standard for screening and monitoring cerebral meningiomas is MRI with injection of gadoline-contrast product. However, the use of some of these products is problematic, due to gadolinium deposits observed in patients who have had several injections during their lifetime, especially in patients followed for multiple sclerosis. Recently, the French National Agency for the Safety of Medicines and Health Products (ANSM) issued recommendations concerning the screening of meningiomas in patients at risk, particularly in people treated with cyproterone acetate. It is a synthetic progestogen steroid with anti-androgenic properties. It is used to treat hyperandrogenic syndromes in women or in the palliative treatment of prostate cancer in men. Its long-term use seems to be associated with a significant over-risk of developing meningiomas, brain tumours affecting meninges. This increased risk is multiplied by 7 in women exposed to high doses of cyproterone acetate, and by 20 over a cumulative dose of 60 grams, or about 5 years of treatment at 50 mg/day or 10 years at 25 mg/day. The ANSM recommends that a cerebral MRI be performed at the beginning of treatment for all patients, as well as a control MRI renewed at 5 years and then every 2 years if the MRI at 5 years is normal. These recommendations will lead to a large number of MRIs involving an injection of contrast agent in this population, with potential immediate or delayed serious adverse effects. New techniques, such as Arterial Spin Labelling (ASL), or black blood sequences optimized for contrast detection, have been developed. These could detect meningeal anomalies and more particularly meningiomas without contrast injection, or with a significantly lower dose of contrast agent. These techniques have not been specifically studied for screening or monitoring meningeal lesions, but it seems relevant and important to be able to validate protocols that reduce gadolinium doses given the high number of screening and follow-up MRIs in the general population. Patients presenting for brain MRI screening or meningioma follow-up will have the usual MRI sequences for their management, and the sequences performed at 1/6th of the standard dose of Gadolinium that are added for research. These new sequences will add approximately 6 minutes of additional examination time.

Conditions

Meningioma

Outcome Measures

Primary Outcomes (1)

• Evaluate the diagnostic concordance in terms of meningioma detection between the 3T MRI sequences with a Gadolinium injection reduced to 1/6th and the full dose sequences (Gold Standard).

  1 day

Interventions

sequences T1 FE OTHER

T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.

Also known as: T1 TFE sequences

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients presenting to the radiology department of the Adolphe de Rothschild Foundation for an MRI, as part of a screening or monitoring of meningioma

You may qualify if:

• Patient over 18 years of age
• Patient performing MRI as part of a screening or follow-up of known meningioma
• Express consent to participate in the study

You may not qualify if:

• Contraindication for MRI (electrical device, metallic foreign body, claustrophobia)
• Known hypersensitivity to the contrast medium (Gadolinium)
• Known renal failure: glomerular filtration rate \<30mL/min
• Patient benefiting from a legal protection measure
• Pregnant or breastfeeding woman

Sponsors & Collaborators

• Fondation Ophtalmologique Adolphe de Rothschild: lead

Study Sites (10)

CHU de Grenoble

Grenoble, Grenoble, 38100, France

Location

CHU de Limoges

Limoges, Limoges, 87042, France

Location

CHU de Lyon

Lyon, Lyon, 69495, France

Location

CHU de Nantes

Nantes, Nantes, 44800, France

Location

Fondation ophtalmique Adolphe de Rothschild

Paris, Paris, 75019, France

Location

CHU de Rennes

Rennes, Rennes, 35033, France

Location

CHU de Rouen

Rouen, Rouen, 76000, France

Location

CHU de Strasbourg

Strasbourg, Strasbourg, 67000, France

Location

CHU de Tours

Tours, Tours, France

Location

CHU de Bordeaux

Bordeaux, 33076, France

Location

MeSH Terms

Conditions

Meningioma

Condition Hierarchy (Ancestors)

Neoplasms, Nerve Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Nervous System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2019
• First Posted: October 2, 2019
• Study Start: December 23, 2019
• Primary Completion: July 18, 2025
• Study Completion: July 18, 2025
• Last Updated: January 5, 2026

Record last verified: 2025-12

Locations

FR (10)